Could a heart pill beat long COVID fatigue? new trial aims to find out.

NCT ID NCT05697640

Ongoing Symptom relief Sponsor: Charite University, Berlin, Germany Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug vericiguat, already approved for heart failure, can improve physical function and reduce fatigue in people aged 18-50 with post-COVID syndrome. About 104 participants will receive either vericiguat or a placebo for 10 weeks, then be followed for 30 days. The goal is to see if the drug helps with daily activities like walking and carrying groceries.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-COVID ME/CFS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

long COVID-19 myalgic encephalomeyelitis/chronic fatigue syndrome post-COVID-19 disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POST-COVID ME/CFS

Contacts and locations

Locations

Charité - Universitätsmedizin Berlin

Berlin, State of Berlin, 10117, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.